ArticleInternational journal of molecular sciences2026
Recombinant Antigen for Newcastle Disease Virus Vaccine Focusing on Currently Circulating Virus Variants.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Newcastle disease virus (NDV) causes a highly contagious avian infection and is characterised by its high genetic diversity and mutation rate. Currently applied vaccines are based on NDV genotypes I and II, which are considerably distinct from the circulating pathogenic genotypes, of which genotype VII is predominant, and therefore, they may not provide complete protection for birds or stop virus transmission. This work is a proof-of-concept study aiming to develop a genotype VII-focused recombinant antigen for a vaccine targeting relevant NDV strains. The research primarily focuses on novel antigen design based on the bioinformatics analysis of recent circulating isolates. Haemagglutinin-neuraminidase (HN) is one of the two main NDV antigens. Two HN fragments ("1"-341-368 aa and "2"-239-257 aa) were selected due to the presence of linear neutralising epitopes. An approach focusing on using a number of selected-fragment variants simultaneously was applied for the first time. The resulting antigen Castle1 encompasses the sequence diversity of most circulating isolates. Preliminary immunological evaluation showed that antibodies from Castle1-immunised animals possessed haemagglutination inhibition activity and interacted with NDV of genotypes I and VII. That makes Castle1 a promising antigen for the further development of a vaccine for preventing ongoing and incoming NDV outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.